Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Recent & Breaking News (PINL:VBIVQ)

VBI Vaccines Provides an Update on its Restructuring Proceedings

Business Wire August 2, 2024

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

Business Wire July 30, 2024

VBI Vaccines Announces Results of Annual General Meeting

Business Wire June 25, 2024

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

Business Wire May 29, 2024

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

Business Wire May 22, 2024

VBI Vaccines Reports First Quarter 2024 Financial Results

Business Wire May 15, 2024

VBI Vaccines Reports Full Year 2023 Financial Results

Business Wire April 16, 2024

VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Business Wire April 11, 2024

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Business Wire April 9, 2024

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

Business Wire April 3, 2024

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

Business Wire April 2, 2024

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

Business Wire February 14, 2024

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

Business Wire November 20, 2023

VBI Vaccines Reports Third Quarter 2023 Financial Results

Business Wire November 14, 2023

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

Business Wire October 26, 2023

VBI Vaccines' Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern

Business Wire September 27, 2023

VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Business Wire September 7, 2023

VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B

Business Wire September 6, 2023

VBI Vaccines Reports Second Quarter 2023 Financial Results

Business Wire August 14, 2023

 VBI Vaccines Announces Closing of Underwriters' Partial Exercise of Option to Purchase Additional Common Shares

Business Wire July 24, 2023